Social services
NIH to Grant Exclusive Patent License for Ebola Neutralizing Monoclonal Antibody
The National Institute of Allergy and Infectious Diseases (NIAID) is considering granting an exclusive patent license to Ridgeback Biotherapeutics, L.P. for the development, production, and commercialization of an Ebola neutralizing monoclonal antibody, mAb114, for the treatment of Ebola virus disease in humans. This license would cover the use of